Citations

Mayo Clinic

Showing 10 of 108551 citations.

AL amyloidosis response: a move in the “light” direction
Dispenzieri, Angela

Blood | March 28, 2024 | Volume: 143 | Issue: 13 | Pages: 1204-1206

10.1182/blood.2023023393 | PMID 38546635 Get It

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
Appleman, Leonard J. , Kim, Se Eun , Harris, Wayne , Pal, Sumanta K. , Pins, Michael R., Kolesar, Jill , Agarwal, Neeraj , Vaena, Daniel A. , Ryan, Christopher W. , Hashmi, Mehmood, Costello, Brian A. , Cella, David , DiPaola, Robert S. , Parikh, Rahul A , Vaena, Daniel A , Costello, Brian A , Cella, David , Dutcher, Janice P. , Haas, Naomi B , Wagner, Lynne , Agarwal, Archana M , Appleman, Leonard , Wagner, Lynne I. , Carducci, Michael A.

Journal of Clinical Oncology | March 28, 2024 | Volume: 42 | Issue: 17 | Pages: 2061-2070

10.1200/jco.23.01544 | PMID 38531002 Get It

PURPOSE Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular endothelial growth factor receptor and other kinases that improves progression-free survival in patients with metastatic RCC (mRCC). We conducted a randomized, double-blind, placebo-controlled multicenter study to test whether pazopanib would improve disease-free survival (DFS) in patients with mRCC rendered NED after metastasectomy. PATIENTS AND METHODS Patients with NED after metastasectomy were randomly assigned 1:1 to receive pazopanib 800 mg once daily versus placebo for 52 weeks. The study was designed to observe an improvement in DFS from 25% to 45% with pazopanib at 3 years, corresponding to 42% reduction in the DFS event rate. RESULTS From August 2012 to July 2017, 129 patients were enrolled. The study was unblinded after 83 DFS events (92% information). The study did not meet its primary end point. An updated analysis at 60.5-month median follow-up from random assignment (95% CI, 59.3 to 71.0) showed that the 3-year DFS was 27.4% (95% CI, 17.9 to 41.7) for pazopanib and 21.9% (95% CI, 13.3 to 36.2) for placebo. Hazard ratio (HR) for DFS was 0.90 ([95% CI, 0.60 to 1.34]; Pone-sided = .29) in favor of pazopanib. Three-year overall survival (OS) was 81.9% (95% CI, 72.7 to 92.2) for pazopanib and 91.4% (95% CI, 84.4 to 98.9) for placebo. The HR for OS was 2.55 (95% CI, 1.23 to 5.27) in favor of placebo ( Ptwo-sided = .012). Health-related quality-of-life measures deteriorated in the pazopanib group during the treatment period. CONCLUSION Pazopanib did not improve DFS as the primary end point compared with blinded placebo in patients with mRCC with NED after metastasectomy. In addition, there was a concerning trend favoring placebo in OS.
Applied Artificial Intelligence in Healthcare: A Review of Computer Vision Technology Application in Hospital Settings
Lindroth, Heidi , Nalaie, Keivan , Raghu, Roshini , Ayala, Ivan N. , Busch, Charles, Franco, Pablo Moreno , Diedrich, Daniel A. , Pickering, Brian W. , Herasevich, Vitaly , Moreno Franco, Pablo , Herasevich, Vitaly , Ayala, Iván Nicolas , Lindroth, Heidi , Bhattacharyya, Anirban

Journal of Imaging | March 28, 2024 | Volume: 10 | Issue: 4 | Pages: 81

10.3390/jimaging10040081 | PMID 38667979 Get It

Computer vision (CV), a type of artificial intelligence (AI) that uses digital videos or a sequence of images to recognize content, has been used extensively across industries in recent years. However, in the healthcare industry, its applications are limited by factors like privacy, safety, and ethical concerns. Despite this, CV has the potential to improve patient monitoring, and system efficiencies, while reducing workload. In contrast to previous reviews, we focus on the end-user applications of CV. First, we briefly review and categorize CV applications in other industries (job enhancement, surveillance and monitoring, automation, and augmented reality). We then review the developments of CV in the hospital setting, outpatient, and community settings. The recent advances in monitoring delirium, pain and sedation, patient deterioration, mechanical ventilation, mobility, patient safety, surgical applications, quantification of workload in the hospital, and monitoring for patient events outside the hospital are highlighted. To identify opportunities for future applications, we also completed journey mapping at different system levels. Lastly, we discuss the privacy, safety, and ethical considerations associated with CV and outline processes in algorithm development and testing that limit CV expansion in healthcare. This comprehensive review highlights CV applications and ideas for its expanded use in healthcare.
Current and Future Applications of Arterial Spin Labeling MRI in Cerebral Arteriovenous Malformations
Simone, Matteo De , Fontanella, Marco Maria , Choucha, Anis , Schaller, Karl , Machi, Paolo , Bijlenga, Philippe , Kurz, Felix T. , Maria, Lucio De , De Simone, Matteo , Bijlenga, Philippe , De Maria, Lucio , Fontanella, Marco Maria , Lanzino, Giuseppe , Lövblad, Karl‐Olof

Biomedicines | March 28, 2024 | Volume: 12 | Issue: 4 | Pages: 753

10.3390/biomedicines12040753 | PMID 38672109 Get It

Arterial spin labeling (ASL) has emerged as a promising noninvasive tool for the evaluation of both pediatric and adult arteriovenous malformations (AVMs). This paper reviews the advantages and challenges associated with the use of ASL in AVM assessment. An assessment of the diagnostic workup of AVMs and their variants in both adult and pediatric populations is proposed. Evaluation after treatments, whether endovascular or microsurgical, was similarly examined. ASL, with its endogenous tracer and favorable safety profile, offers functional assessment and arterial feeder identification. ASL has demonstrated strong performance in identifying feeder arteries and detecting arteriovenous shunting, although some studies report inferior performance compared with digital subtraction angiography (DSA) in delineating venous drainage. Challenges include uncertainties in sensitivity for specific AVM features. Detecting AVMs in challenging locations, such as the apical cranial convexity, is further complicated, demanding careful consideration due to the risk of underestimating total blood flow. Navigating these challenges, ASL provides a noninvasive avenue with undeniable merits, but a balanced approach considering its limitations is crucial. Larger-scale prospective studies are needed to comprehensively evaluate the diagnostic performance of ASL in AVM assessment.
Nonalbumin Proteinuria in a Patient with Slowly Worsening Kidney Function
Schoonmaker, Jennifer A. , Ryan, Margaret , Bhasin, Bhavna , Ryan, Margaret S, Bhasin-Chhabra, Bhavna

Kidney360 | March 28, 2024 | Volume: 5 | Issue: 3 | Pages: 481-482

10.34067/kid.0000000000000338 | PMID 38546983 Get It

Risk Factors for Thyroid Dysfunction in Pregnancy: An Individual Participant Data Meta-Analysis
Osinga, J. , Liu, Yindi , Vafeiadi, Marina , Tao, Fangbiao , López‐Bermejo, Abel , Boucai, Laura , Hisada, Aya , Yoshinaga, Jun , Broeren, Maarten A.C., Itoh, Sachiko, Kishi, Reiko , Ashoor, Ghalia, Veltri, Flora, Lu, Xuemian , Taylor, Peter , Chatzi, Leda , Grineva, Elena , Ghafoor, Farkhanda, Pirzada, Amna, Kianpour, Maryam , Oken, Emily , Suvanto, Eila, Irizar, Amaia , Boelaert, Kristien , Brenta, Gabriela , Dhillon‐Smith, Rima , Dosiou, Chrysoula , Eaton, Jennifer L., Guan, Haixia , Nguyen, Caroline T. , Pop, Victor J.M. , Walsh, John P. , D’Alton, Mary E. , Carty, David , Delles, Christian , Alexander, Erik K. , Pearce, Elizabeth N. , Derakhshan, Arash , Korevaar, Tim I.M. , Osinga, Joris A J , Boucai, Laura , Feldt-Rasmussen, Ulla , Brenta, Gabriela , Guan, Haixia , Lee, Sun Y , Walsh, John P , Nelson, Scott McGill , Bliddal, Sofie , Pearce, Elizabeth N , Taylor, Peter N , López-Bermejo, Abel , Oken, Emily , Dosiou, Chrysoula , Männistö, Tuija , Vaidya, Bijay , Vrijkotte, Tanja G. M. , Mosso, Lorena , Bassols, Judit , Aminorroaya, Ashraf , Chen, Liangmiao , Brown, Suzanne J , Popova, Polina , Hattersley, Andrew T. , Rebagliato, Marisa , Galán, Isolina Riaño , Vrijheid, Martine , Delgado-Saborit, Juana María , Fernández‐Somoano, Ana , Santa‐Marina, Loreto , Maraka, Spyridoula , Morris, Lilah F. , Shan, Zhongyan , Guxens, Mònica , Nicolaides, Kypros H. , Visser, W. Edward , Nelson, Scott M. , Chaker, Layal , Richards, C. Sue , Peeters, Robin P. , Bliddal, Sofie , Huang, Kun , Poppe, Kris Gustave

Thyroid® | March 28, 2024 | Volume: 34 | Issue: 5 | Pages: 646-658

10.1089/thy.2023.0646 | PMID 38546971 Get It

Background: International guidelines recommend targeted screening to identify gestational thyroid dysfunction. However, currently used risk factors have questionable discriminative ability. We quantified the risk for thyroid function test abnormalities for a subset of risk factors currently used in international guidelines. Methods: We included prospective cohort studies with data on gestational maternal thyroid function and potential risk factors (maternal age, body mass index [BMI], parity, smoking status, pregnancy through in vitro fertilization, twin pregnancy, gestational age, maternal education, and thyroid peroxidase antibody [TPOAb] or thyroglobulin antibody [TgAb] positivity). Exclusion criteria were pre-existing thyroid disease and use of thyroid interfering medication. We analyzed individual participant data using mixed-effects regression models. Primary outcomes were overt and subclinical hypothyroidism and a treatment indication (defined as overt hypothyroidism, subclinical hypothyroidism with thyrotropin >10 mU/L, or subclinical hypothyroidism with TPOAb positivity). Results: The study population comprised 65,559 participants in 25 cohorts. The screening rate in cohorts using risk factors currently recommended (age >30 years, parity ≥2, BMI ≥40) was 58%, with a detection rate for overt and subclinical hypothyroidism of 59%. The absolute risk for overt or subclinical hypothyroidism varied <2% over the full range of age and BMI and for any parity. Receiver operating characteristic curves, fitted using maternal age, BMI, smoking status, parity, and gestational age at blood sampling as explanatory variables, yielded areas under the curve ranging from 0.58 to 0.63 for the primary outcomes. TPOAbs/TgAbs positivity was associated with overt hypothyroidism (approximate risk for antibody negativity 0.1%, isolated TgAb positivity 2.4%, isolated TPOAb positivity 3.8%, combined antibody positivity 7.0%; p < 0.001), subclinical hypothyroidism (risk for antibody negativity 2.2%, isolated TgAb positivity 8.1%, isolated TPOAb positivity 14.2%, combined antibody positivity 20.0%; p < 0.001) and a treatment indication (risk for antibody negativity 0.2%, isolated TgAb positivity 2.2%, isolated TPOAb positivity 3.0%, and combined antibody positivity 5.1%; p < 0.001). Twin pregnancy was associated with a higher risk of overt hyperthyroidism (5.6% vs. 0.7%; p < 0.001). Conclusions: The risk factors assessed in this study had poor predictive ability for detecting thyroid function test abnormalities, questioning their clinical usability for targeted screening. As expected, TPOAb positivity (used as a benchmark) was a relevant risk factor for (subclinical) hypothyroidism. These results provide insights into different risk factors for gestational thyroid dysfunction.
Nonconventional Dysplasia is Frequently Associated With Goblet Cell Deficient and Serrated Variants of Colonic Adenocarcinoma in Inflammatory Bowel Disease
Xiao, Andrew , Yozu, Masato , Yassan, Lindsay , Westerhoff, Maria , Sejben, Anita , Lauwers, Gregory Y. , Choi, Won‐Tak , Xiao, Andrew, Kővári, Bence , Liao, Xiaoyan , Salomao, Marcela

American Journal of Surgical Pathology | March 28, 2024 | Volume: 48 | Issue: 6 | Pages: 691-698

10.1097/pas.0000000000002217 | PMID 38546105 Get It

Various subtypes of nonconventional dysplasia have been recently described in inflammatory bowel disease (IBD). We hypothesized that goblet cell deficient dysplasia and serrated dysplasia may be the primary precursor lesions for goblet cell deficient (GCDAC) and serrated (SAC) variants of colonic adenocarcinoma, respectively. Clinicopathologic features of 23 GCDAC and 10 SAC colectomy cases were analyzed. All dysplastic lesions found adjacent to the colorectal cancers (n = 22 for GCDACs and n = 10 for SACs) were subtyped as conventional, nonconventional, or mixed-type dysplasia. As controls, 12 IBD colectomy cases with well to moderately differentiated adenocarcinoma that lacked any mucinous, signet ring cell, low-grade tubuloglandular, or serrated features while retaining goblet cells throughout the tumor (at least 50% of the tumor) were evaluated. The cohort consisted of 19 (58%) men and 14 (42%) women, with a mean age of 53 years and a long history of IBD (mean duration: 18 y). Twenty-seven (82%) patients had ulcerative colitis. GCDACs (57%) were more often flat or invisible than SACs (10%) and controls (25%; P = 0.023). The GCDAC and SAC groups were more likely to show lymphovascular invasion (GCDAC group: 52%, SAC group: 50%, control group: 0%, P = 0.001) and lymph node metastasis (GCDAC group: 39%, SAC group: 50%, control group: 0%, P = 0.009) than the control group. Notably, GCDACs and SACs were more frequently associated with nonconventional dysplasia than controls (GCDAC group: 77%, SAC group: 40%, control group: 0%, P < 0.001). Goblet cell deficient dysplasia (73%) was the most prevalent dysplastic subtype associated with GCDACs (P = 0.049), whereas dysplasias featuring a serrated component (60%) were most often associated with SACs (P = 0.001). The GCDAC group (75%) had a higher rate of macroscopically flat or invisible synchronous dysplasia compared with the SAC (20%) and control (33%) groups (P = 0.045). Synchronous dysplasia demonstrated nonconventional dysplastic features more frequently in the GCDAC (69%) and SAC (40%) groups compared with the control group (0%; P = 0.016). In conclusion, goblet cell deficient dysplasia and dysplasias featuring a serrated component could potentially serve as high-risk markers for GCDACs and SACs, respectively.
Neuroinvasive West Nile Virus Infection in Immunosuppressed and Immunocompetent Adults
Mbonde, Amir A. , Gritsch, David , Harahsheh, Ehab , Kasule, Sabirah N, Hasan, Shemonti , Parsons, Angela, Zhang, Nan , Butterfield, Richard , Shiue, Harn , Norville, Kathryn , Reynolds, Jenna , Vikram, Holenarasipur R. , Chong, Brian W. , Grill, Marie , Norville, Kathryn A, Reynolds, Jenna L, Grill, Marie F, Vikram, Holenarasipur R. , Shiue, Harn J

JAMA Network Open | March 28, 2024 | Volume: 7 | Issue: 3 | Pages: e244294

10.1001/jamanetworkopen.2024.4294 | PMID 38546642 Get It

Importance West Nile virus (WNV) is the leading cause of human arboviral disease in the US, peaking during summer. The incidence of WNV, including its neuroinvasive form (NWNV), is increasing, largely due to the expanding distribution of its vector, the Culex mosquito, and climatic changes causing heavy monsoon rains. However, the distinct characteristics and outcomes of NWNV in individuals who are immunosuppressed (IS) and individuals who are not IS remain underexplored. Objective To describe and compare clinical and radiographic features, treatment responses, and outcomes of NWNV infection in individuals who are IS and those who are not IS. Design, Setting, and Participants This retrospective cohort study used data from the Mayo Clinic Hospital system collected from July 2006 to December 2021. Participants were adult patients (age ≥18 years) with established diagnosis of NWNV infection. Data were analyzed from May 12, 2020, to July 20, 2023. Exposure Immunosuppresion. Main Outcomes and Measures Outcomes of interest were clinical and radiographic features and 90-day mortality among patients with and without IS. Results Of 115 participants with NWNV infection (mean [SD] age, 64 [16] years; 75 [66%] male) enrolled, 72 (63%) were not IS and 43 (37%) were IS. Neurologic manifestations were meningoencephalitis (98 patients [85%]), encephalitis (10 patients [9%]), and myeloradiculitis (7 patients [6%]). Patients without IS, compared with those with IS, more frequently reported headache (45 patients [63%] vs 18 patients [42%]) and myalgias (32 patients [44%] vs 9 patients [21%]). In contrast, patients with IS, compared with those without, had higher rates of altered mental status (33 patients [77%] vs 41 patients [57%]) and myoclonus (8 patients [19%] vs 8 patients [4%]). Magnetic resonance imaging revealed more frequent thalamic T2 fluid-attenuated inversion recovery hyperintensities in individuals with IS than those without (4 patients [11%] vs 0 patients). Individuals with IS had more severe disease requiring higher rates of intensive care unit admission (26 patients [61%] vs 24 patients [33%]) and mechanical ventilation (24 patients [56%] vs 22 patients [31%]). The 90-day all-cause mortality rate was higher in the patients with IS compared with patients without IS (12 patients [28%] vs 5 patients [7%]), and this difference in mortality persisted after adjusting for Glasgow Coma Scale score (adjusted hazard ratio, 2.22; 95% CI, 1.07-4.27; P = .03). Individuals with IS were more likely to receive intravenous immunoglobulin than individuals without IS (12 individuals [17%] vs 24 individuals [56%]), but its use was not associated with survival (hazard ratio, 1.24; 95% CI, 0.50-3.09; P = .64). Conclusions and Relevance In this cohort study of individuals with NWNV infection, individuals with IS had a higher risk of disease complications and poor outcomes than individuals without IS, highlighting the need for innovative and effective therapies to improve outcomes in this high-risk population.
Perspectives of Oncologists on the Ethical Implications of Using Artificial Intelligence for Cancer Care
Walsh, Thomas , Kehl, Kenneth L. , Abel, Gregory A. , Sharp, Richard, Hantel, Andrew , Marron, Jonathan M. , Sharp, Richard R. , Van Allen, Eliezer M

JAMA Network Open | March 28, 2024 | Volume: 7 | Issue: 3 | Pages: e244077

10.1001/jamanetworkopen.2024.4077 | PMID 38546644 Get It

Importance Artificial intelligence (AI) tools are rapidly integrating into cancer care. Understanding stakeholder views on ethical issues associated with the implementation of AI in oncology is critical to optimal deployment. Objective To evaluate oncologists’ views on the ethical domains of the use of AI in clinical care, including familiarity, predictions, explainability (the ability to explain how a result was determined), bias, deference, and responsibilities. Design, Setting, and Participants This cross-sectional, population-based survey study was conducted from November 15, 2022, to July 31, 2023, among 204 US-based oncologists identified using the National Plan &amp;amp; Provider Enumeration System. Main Outcomes and Measures The primary outcome was response to a question asking whether participants agreed or disagreed that patients need to provide informed consent for AI model use during cancer treatment decisions. Results Of 387 surveys, 204 were completed (response rate, 52.7%). Participants represented 37 states, 120 (63.7%) identified as male, 128 (62.7%) as non-Hispanic White, and 60 (29.4%) were from academic practices; 95 (46.6%) had received some education on AI use in health care, and 45.3% (92 of 203) reported familiarity with clinical decision models. Most participants (84.8% [173 of 204]) reported that AI-based clinical decision models needed to be explainable by oncologists to be used in the clinic; 23.0% (47 of 204) stated they also needed to be explainable by patients. Patient consent for AI model use during treatment decisions was supported by 81.4% of participants (166 of 204). When presented with a scenario in which an AI decision model selected a different treatment regimen than the oncologist planned to recommend, the most common response was to present both options and let the patient decide (36.8% [75 of 204]); respondents from academic settings were more likely than those from other settings to let the patient decide (OR, 2.56; 95% CI, 1.19-5.51). Most respondents (90.7% [185 of 204]) reported that AI developers were responsible for the medico-legal problems associated with AI use. Some agreed that this responsibility was shared by physicians (47.1% [96 of 204]) or hospitals (43.1% [88 of 204]). Finally, most respondents (76.5% [156 of 204]) agreed that oncologists should protect patients from biased AI tools, but only 27.9% (57 of 204) were confident in their ability to identify poorly representative AI models. Conclusions and Relevance In this cross-sectional survey study, few oncologists reported that patients needed to understand AI models, but most agreed that patients should consent to their use, and many tasked patients with choosing between physician- and AI-recommended treatment regimens. These findings suggest that the implementation of AI in oncology must include rigorous assessments of its effect on care decisions as well as decisional responsibility when problems related to AI use arise.